Loading - Please wait
• How can CI support the BD&L process?
• How can MA and payer discussions complement CI in this process?
• How can Payer research input in the forecasting?
• Valuation of an asset using CI
• Understand how competitive strategy should evolve as a brand matures and how this will inevitably impact the product ‘sale’
• This interactive session will help you recognize how the external environment, including competitor and customer behaviour might develop as a brand matures, and appreciate the different challenges and opportunities that this presents to a brand
• Gain an awareness of how the customer perception of ‘value’ will also change as the competitive landscape changes and how your field force strategy must be adapted to ensure your brand stays relevant
• In addition, understand how you can translate the movements of your competitors to all internal stakeholders to ensure internal buy-in to the value of CI, as well as encourage the CI process to be as collaborative as possible across all levels of the organisation
i. Grasp how to systematically approach scenario planning
ii. Leverage and apply fundamental tools utilized during the scenario planning process
iii. Prepare your organization for external threats and internal issue
iv. Identify opportunities and align YOUR organization for the challenges ahead
v. Prioritize activities, focus areas and initiatives
In fact, L.E.K. analysis shows that total sales and market cap of pharma companies are negative predictors of total shareholder returns. A pipeline productivity analysis also highlights that the number of product approvals required to achieve sufficient growth targets for large pharmas is most likely unachievable.
To address these challenges, large pharmas may further consolidate to externally fill pipeline gaps, diversify beyond pharmaceuticals to access adjacent profit segments, deconsolidate, or restructure around a smaller revenue base of high value therapeutic areas.
Understanding the key challenges of scale and applying the learnings from this analysis will enable large pharma executives to sustain growth and maximize shareholder value creation.
In addition, the ever present issue of competing internal urgencies and an expanding group of relevant multidisciplinary stakeholders often makes best practice LCM difficult to implement. In an era of patent cliffs, increasingly competitive landscapes and shrinking pipelines capturing maximal value from every product launch is critical. With only a third of launches meeting or exceeding analyst expectations, the challenge remains considerable. In many cases the success of a brand launch determines the success of the product but increasingly so is market success defined by the LCM strategies implemented post-launch. This talk will explore the critical success factors that form the basis of a good LCM strategy within this new era.
The speaker will be highlighting the critical choices to be made in the process, the challenges faced in balancing short and long term needs, and demonstrating how this has been successfully implemented in his organization today.
Understanding the competitive market dynamics of manufacturing intelligence is a highly actionable and leverage-able means to influence brand, franchise and corporate level strategy and tactical implementation. In this talk, David Alderman, President of Molekule Consulting will detail the types of competitive and market intelligence that can be leveraged by biopharmaceutical players to be better informed and positioned for sustainable success in the biopharmaceutical competitive sandbox.
Mr. Alderman will demonstrate the power and action-ability of manufacturing and supply chain logistics intelligence through an evidence-based and case study backed lecture. Whether local, regional or global in terms of scope and scale, Mr. Alderman will speak to how manufacturing intelligence is key to both ethical and generic/biosimilar biopharmaceutical companies’ strategies, tactics and planning, forward-looking.
How to build up a successful Multichannel going to market business model including digital in the value proposition and through concrete and usable tools.
You will learn what type of data and intelligence you need to optimize your targeted therapy launch and how to ensure your teams are informed once in the market.
B) Leveraging clinical information package, regulatory and commercial capabilities to design an overall biosimilar strategy
However, it is also a market beset by pipeline failures, proof of concept is highly elusive. Joanne will argue that innovation beyond drug development is required in a successful future landscape. Indeed, rather than engaging out and out competition, collaborations are the route some companies are taking to make a difference. To innovate and be successful requires highly strategic thinking, and a deep understanding of the future landscape and its potential impact on the market. Joanne will provide some examples of strategic game-play that can be successfully applied to CNS as well as other therapy areas.
The first was a collaboration with Signals Group, to understand the patient experience with the generics of one of our originator brands, as we were interested in knowing what modifications generic companies had pursued to allow them to achieve the perception of differentiation with the group of patients UCB was also interested in. In the second project we collaborated with Voxx Analytics to identify every single epilepsy scientist, KOL and influencer in the world and how they were shaping and influencing the space of epilepsy.
The session will focus on how to apply the Win/Loss Methodology to the Life Science industry in order optimize and refine messaging, drive sales, and monitor the competition.
3. Dynamics & Outlook
Can you guarantee a successful project outcome that meets your requirements? Should you go with the tried and trusted option, or should you explore the variety of alternatives?
Pick the right vendor, and you can act strategically on the insights gained; establish a solid, ongoing relationship with the vendor; boost the profile of your CI team, and garner greater support for CI activities from the leadership.
Get it wrong, and not only could you miss out on important knowledge or insights, but you could damage your reputation, or lose support and budget from management.
This round table discussion aims to explore the many factors to consider during selection- such as budget, timelines, scope, specific expertise and personal relationships/bias; and the building and maintaining of good relationships with multiple vendors.
From the vendor side, we look for insights on the components required to become the preferred choice and bid successfully for a potentially lucrative project.
However, we realized that many of these threats are not properly quantified in terms of business impact, are not widely recognized across the organisation and as a consequence counter-actions are not always planned to face them.
For this reason, we have run in 2015 a project aimed at thoroughly mapping all the key competitive threats involving marketing & sales and R&D people, at properly quantify them and at defining appropriate strategies to face them, by integrating the analysis in key strategic and commercial projects.
This presentation will focus on what measures can be taken, how information can be divested and shared, and with whom. These events and implications cut across many industries, including pharma, and provide insightful learnings.
It allows your organization’s CI experts to spend less time finding information, allowing them to spend more time customizing a specific lens along with their targeted commentaries. CI lens brings actionable intelligence to decision makers!
You need to monitor and analyse many topics among which clinical trials, innovations, drug safety issues, side effects, product launch campaigns, scientific publications, etc. And all of this supported by bespoke deliverables. We will share in this talk best practices from pharma companies having managed this process successfully.
The session will enable you to gain an up to date view of the direction this market is taking in terms of patient activation, improving compliance, data analysis and storage, which Apps are changing the face healthcare and prescribers decision making processes as well as how your competitors are integrating mHealth strategies into their business models. Dig Worldwide will also examine the potential threat from new entrants outside of the industry.
In this panel session, the Informa Pharma and Healthcare team and industry expert will come together to discuss how the competitive landscape of clinical trials and drug development evolved during 2015. Panel participants will discuss key trends observed in 2015 and identify some not-so-obvious trends. Where did we succeed and where is there room for improvement? Moderated by Informa’s Content Director Mike Ward, this session promises to be a lively and informative discussion that will leave you with a variety of viewpoints on the top stories of 2015 and what they might mean for 2016 and beyond.